Supernus Pharmaceuticals (SUPN) VP Victor Vaughn Sells 60,000 Shares

Supernus Pharmaceuticals (NASDAQ:SUPN) VP Victor Vaughn sold 60,000 shares of the stock in a transaction dated Thursday, April 5th. The shares were sold at an average price of $45.33, for a total transaction of $2,719,800.00. Following the completion of the transaction, the vice president now directly owns 24,344 shares in the company, valued at $1,103,513.52. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Victor Vaughn also recently made the following trade(s):

  • On Friday, January 12th, Victor Vaughn sold 5,750 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $45.03, for a total transaction of $258,922.50.
  • On Tuesday, January 9th, Victor Vaughn sold 15,000 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $42.04, for a total transaction of $630,600.00.

Shares of SUPN opened at $45.65 on Thursday. Supernus Pharmaceuticals has a 12 month low of $29.95 and a 12 month high of $50.04. The company has a market cap of $2,337.21, a PE ratio of 36.23 and a beta of 1.11.



Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.18. Supernus Pharmaceuticals had a net margin of 18.95% and a return on equity of 28.07%. The company had revenue of $88.44 million for the quarter, compared to analysts’ expectations of $87.84 million. research analysts predict that Supernus Pharmaceuticals will post 1.85 EPS for the current fiscal year.

Several research analysts have weighed in on the stock. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 21st. ValuEngine raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Berenberg Bank assumed coverage on shares of Supernus Pharmaceuticals in a report on Thursday, February 1st. They set a “buy” rating and a $66.00 target price on the stock. B. Riley reaffirmed a “buy” rating and set a $54.00 target price on shares of Supernus Pharmaceuticals in a report on Thursday, January 18th. Finally, Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $51.36.

Several institutional investors and hedge funds have recently made changes to their positions in SUPN. Public Employees Retirement Association of Colorado acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $188,000. Elkfork Partners LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $217,000. Sigma Planning Corp acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $219,000. Parametrica Management Ltd acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $247,000. Finally, Flinton Capital Management LLC boosted its position in shares of Supernus Pharmaceuticals by 26.5% during the 4th quarter. Flinton Capital Management LLC now owns 6,944 shares of the specialty pharmaceutical company’s stock worth $277,000 after acquiring an additional 1,456 shares in the last quarter. 96.30% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was first posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://dakotafinancialnews.com/2018/04/12/supernus-pharmaceuticals-supn-vp-victor-vaughn-sells-60000-shares.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply